Liver Disease Treatment Market Report and Forecast 2024-2032

Liver Disease Treatment Market Size

The liver disease treatment market was valued at USD 20.14 billion in 2023, driven by the increasing prevalence of liver disease across the 8 major markets. The market is expected to grow at a CAGR of 10.4% during the forecast period of 2024-2032, with the values likely to reach USD 48.88 billion by 2032.

Liver Disease Treatment Market Outlook

• Recent data reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. This rising burden of liver disease is a major growth driver for effective treatments.

• The surge in the approval of innovative drugs for the treatment of liver disease by the regulatory bodies is a significant market trend.

• The market value is impacted by the rising preference for combination therapies and the advancements in diagnostic technologies.

Liver Disease Treatment Market Overview

A liver disease directly affects the liver and progresses slowly unlike acute liver failure. Untreated liver disease can result in liver cancer or liver failure. Treatments for liver disease can include antiviral drugs to treat hepatitis, steroids for managing liver inflammation, and others. The increasing cases of liver disease due to factors such as obesity, viral infections, and alcohol consumption is a major growth driver of the market. Further, the rising development of novel therapeutics such as immune modulators and gene therapies that offer better clinical benefits are expected to augment the market demand. Moreover, improvements in diagnostic tools including imaging techniques and biomarker tests for diagnosing and monitoring liver diseases is also contributing to the market growth.

Liver Disease Treatment Market Growth Drivers

Rising Prevalence of Liver Diseases to Drive Market Growth

Recent data  reveals that over 100 million individuals in the United States are affected by liver or hepatic disease. It is reported that 4.5 million adults have been diagnosed with liver disease. However, around 80 to 100 million U.S. adults are estimated to have undiagnosed fatty liver disease in varying stages. The increasing prevalence of liver diseases is expected to drive the demand for effective treatment. Additionally, the growing geriatric population, which is more prone to liver diseases, is poised to contribute to the market demand.

Liver Disease Treatment Market Trends

The market is witnessing several trends and developments to improve the current scenario across the 8 major markets. Some of the notable trends are as follows:

Increased Public Health Initiatives to Impact the Market Landscape

The market is witnessing increased awareness campaigns and screening programs by global health organizations and governments in order to promote early diagnosis and treatment of liver disease. Such public health initiatives, especially for diseases like hepatitis B and C, are encouraging more people to seek treatment. These factors are likely to influence the market landscape signficantly.

Surge in FDA Approval to Meet Rising Liver Disease Treatment Market Demand

In March 2024 , Rezdiffra™ developed by biopharma company Madrigal Pharmaceuticals, Inc. became the first and only FDA-approved treatment for noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. Moreover, in February 2024 , GSK plc's investigational candidate bepirovirsen received Fast Track designation for the treatment of chronic hepatitis B (CHB) by the FDA. The surge in the approval of innovative drugs for the treatment of liver disease, supported by the presence of a favorable regulatory environment is a major trend, poised to amplify the market demand in coming years.

Advancements in Diagnostic Technologies Likely to Boost Liver Disease Treatment Market Size

The rising advancements in imaging technologies, such as transient elastography (FibroScan), magnetic resonance elastography (MRE), and multiparametric MRI are experiencing popularity among patients due to their non-invasive assessment of liver fibrosis and steatosis. The increasing availability of non-invasive diagnostic tools is anticipated to contribute to the market growth.

Shift Towards Combination Therapies is Poised to Elevate the Liver Disease Treatment Market Value

There is a growing demand for combination therapies in the market as these treatment approaches often result in improved clinical outcomes. For instance, in cases of Hepatitis C and NASH, the combination of antiviral agents with other drug classes is seen to increase efficacy and reduce drug resistance. Thus, the rising preference for combination therapies is set to shape the market dynamics in the forecast period.

Liver Disease Treatment Market Segmentation

Market Breakup by Treatment Type

• Antiviral Drugs

• Immunosuppressants

• Vaccines

• Immunoglobulins

• Corticosteroids

• Targeted Therapy

• Chemotherapy

• Others

Market Breakup by Disease Type

• Hepatitis

• Autoimmune Diseases

• Non-alcoholic fatty Liver Disease

• Cancer

• Others

Market Breakup by End User

• Hospitals and Clinics

• Diagnostic Laboratories

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Liver Disease Treatment Market Share

Market Segmentation Based on Treatment Type is Anticipated to Witness Substantial Growth

Based on the treatment type, the market is segmented into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy, among others. The antiviral drugs segment covers a significant market share due to the high prevalence of viral hepatitis such as hepatitis B and C. The development of new antiviral agents with higher efficacy and better safety profiles further boosts the market share. Moreover, the chronic nature of hepatitis B and C, if not treated effectively, necessitates long-term antiviral therapy, which is likely to augment the market demand in the forecast period.

Liver Disease Treatment Market Analysis by Region

Based on the region, the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States dominates the market share due to the considerable burden of liver diseases, the presence of advanced healthcare infrastructure, and a strong focus on research and development activities in the region. The high healthcare expenditure allows access to innovative therapies and also supports the development of new treatments in the region. Moreover, the presence of key players in the United States that are engaged in developing antiviral and targeted therapies for liver diseases is expected to bolster the market growth.

Leading Players in the Liver Disease Treatment Market

The key features of the market report comprise the patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading key players. The major companies in the market are as follows:

Abbott Laboratories

American multinational medical devices and health care company Abbott Laboratories is a prominent player in the market. Its drug SILLIVER® (Silymarin)  is indicated for the treatment of liver diseases such as liver cirrhosis, acute hepatitis, and toxic metabolic liver damage. Silymarin is also known to protect against liver damage by general anesthesia.

Bristol-Myers Squibb Company

Headquartered in Princeton, New Jersey, Bristol-Myers Squibb is widely recognized for its innovative treatments including therapies for liver diseases. One of its key medications is the FDA-approved Daklinza (daclatasvir ) taken in combination with sofosbuvir for the treatment of chronic hepatitis C genotype 3.

Gilead Sciences

California-based Gilead Sciences is an American biopharmaceutical company that specializes in the development of antiviral therapies, particularly for liver diseases. Gilead actively collaborates with research institutions and healthcare organizations to boost its research capabilities and expand its portfolio in liver disease treatment.

GlaxoSmithKline PLC

Leading biopharma company GlaxoSmithKline PLC is headquartered in Brentford, United Kingdom, and focuses on the development of vaccine development, antiviral therapies, and innovative treatment approaches for chronic liver conditions.

Other key players in the market include Astellas Pharma Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi AG, AbbVie Inc., and Pfizer Inc.

Key Highlights of the Report

Key Questions Answered in the Liver Disease Treatment Market Report

• What was the liver disease treatment market value in 2023?
• What is the liver disease treatment market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on treatment type?
• What is the market breakup based on disease type?
• Who are the major end users in the market?
• What are the major factors aiding the liver disease treatment market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is expected to experience expedited growth during the forecast period? 
• How do the prevalence and incidence of liver diseases affect the market landscape?
• What are the major liver disease treatment market trends?
• How do the improvements in diagnostic tools impact the market size?
• Which treatment type will dominate the market share? 
• Which disease type is expected to have a high market value in the coming years?
• Which end user is projected to contribute to the highest market growth?
• Who are the key players involved in the liver disease treatment market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?